• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物固体:监管考量的战略方法。

Pharmaceutical solids: a strategic approach to regulatory considerations.

作者信息

Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G

机构信息

Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, Indiana 47907, USA.

出版信息

Pharm Res. 1995 Jul;12(7):945-54. doi: 10.1023/a:1016241927429.

DOI:10.1023/a:1016241927429
PMID:7494814
Abstract

PURPOSE

This review describes a conceptual approach to the characterization of pharmaceutical solids.

METHODS

Four flow charts are presented: (1) polymorphs, (2) hydrates, (3) desolvated solvates, and (4) amorphous forms.

RESULTS

These flow charts (decision trees) are suggested as tools to develop information on pharmaceutical solids for both scientific and regulatory purposes.

CONCLUSIONS

It is hoped that this review will lead to a more direct approach to the characterization of pharmaceutical solids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.

摘要

目的

本综述描述了一种用于表征药物固体的概念性方法。

方法

展示了四个流程图:(1)多晶型物,(2)水合物,(3)去溶剂化溶剂化物,以及(4)无定形形式。

结果

建议将这些流程图(决策树)作为工具,用于为科学和监管目的开发有关药物固体的信息。

结论

希望本综述将带来一种更直接的方法来表征药物固体,并最终加快包含药物固体信息的监管文件的批准。

相似文献

1
Pharmaceutical solids: a strategic approach to regulatory considerations.药物固体:监管考量的战略方法。
Pharm Res. 1995 Jul;12(7):945-54. doi: 10.1023/a:1016241927429.
2
High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.高通量结晶:药物固体的多晶型物、盐、共晶体和溶剂化物
Adv Drug Deliv Rev. 2004 Feb 23;56(3):275-300. doi: 10.1016/j.addr.2003.10.020.
3
Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.药物固体中非晶态/晶态相定量分析技术。
J Pharm Sci. 2006 Aug;95(8):1641-65. doi: 10.1002/jps.20644.
4
Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids.晶体固体中过程诱导无序的定性和定量测定的关键考量因素。
J Pharm Sci. 2014 Sep;103(9):2595-2604. doi: 10.1002/jps.23930. Epub 2014 Mar 12.
5
Estimating the refractive index of pharmaceutical solids using predictive methods.使用预测方法估算药物固体的折射率。
Int J Pharm. 2009 Feb 23;368(1-2):16-23. doi: 10.1016/j.ijpharm.2008.09.044. Epub 2008 Oct 7.
6
Application of mid-IR spectroscopy for the characterization of pharmaceutical systems.中红外光谱在药物体系特性表征中的应用。
Int J Pharm. 2011 Sep 30;417(1-2):3-16. doi: 10.1016/j.ijpharm.2010.12.011. Epub 2010 Dec 15.
7
Physics of amorphous solids.
J Pharm Sci. 2004 Jan;93(1):3-12. doi: 10.1002/jps.10489.
8
Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.药物溶剂化物、水合物和无定形形式:特别关注共晶。
Adv Drug Deliv Rev. 2017 Aug 1;117:25-46. doi: 10.1016/j.addr.2017.03.002. Epub 2017 Mar 22.
9
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.药物固体多晶型的一般原理:超分子视角
Adv Drug Deliv Rev. 2004 Feb 23;56(3):241-74. doi: 10.1016/j.addr.2003.10.005.
10
Crystalline solids.晶体固体。
Adv Drug Deliv Rev. 2001 May 16;48(1):3-26. doi: 10.1016/s0169-409x(01)00097-7.

引用本文的文献

1
Quantitative Solid-State NMR Spectroscopy (qSSNMR) in Pharmaceutical Analysis.药物分析中的定量固态核磁共振光谱法(qSSNMR)
Magn Reson Chem. 2025 Jul;63(8):585-592. doi: 10.1002/mrc.5536. Epub 2025 May 26.
2
Pharmaceutical Sciences: Insights and Observations from Academic Chairs and Vice Chairs.药学:来自学院院长和副院长的见解与观察
AAPS J. 2025 Feb 4;27(1):41. doi: 10.1208/s12248-025-01026-9.
3
Accelerated Development of Pharmaceuticals Past, Present, and Future.药品研发的加速:过去、现在与未来。

本文引用的文献

1
DISSOLUTION BEHAVIOR OF CRYSTALLINE SOLVATED AND NONSOLVATED FORMS OF SOME PHARMACEUTICALS.某些药物的结晶溶剂化物和非溶剂化物形式的溶解行为
J Pharm Sci. 1963 Aug;52:781-91. doi: 10.1002/jps.2600520815.
2
Polymorphism and drug availability. Solubility relationships in the methylprednisolone system.多态性与药物可及性。甲基泼尼松龙系统中的溶解度关系。
J Pharm Sci. 1963 Feb;52:150-3. doi: 10.1002/jps.2600520210.
3
Solid-state nuclear magnetic resonance spectroscopy: theory and pharmaceutical applications.固态核磁共振光谱学:理论与药物应用。
Pharm Res. 2024 Aug;41(8):1547-1555. doi: 10.1007/s11095-024-03737-8. Epub 2024 Aug 6.
4
Characterization and Evaluation of Polymorphic Valnemulin Hydrogen Fumarate.富马酸沃尼妙林多晶型的表征与评价
Curr Drug Deliv. 2025;22(6):798-809. doi: 10.2174/0115672018289236240530095059.
5
Investigating the function and design of molecular materials through terahertz vibrational spectroscopy.通过太赫兹振动光谱研究分子材料的功能与设计。
Nat Rev Chem. 2023 Jul;7(7):480-495. doi: 10.1038/s41570-023-00487-w. Epub 2023 Apr 21.
6
Vapor Sorption and Halogen-Bond-Induced Solid-Form Rearrangement of a Porous Pharmaceutical.一种多孔药物的蒸汽吸附与卤素键诱导的固态形式重排
Cryst Growth Des. 2023 Feb 28;23(4):2628-2633. doi: 10.1021/acs.cgd.2c01464. eCollection 2023 Apr 5.
7
Pharmaceutical Functionalization of Monomeric Ionic Liquid for the Preparation of Ionic Graft Polymer Conjugates.单体离子液体的药物功能化用于离子接枝聚合物缀合物的制备。
Int J Mol Sci. 2022 Nov 25;23(23):14731. doi: 10.3390/ijms232314731.
8
Conformational Trimorphism in an Ionic Cocrystal of Hesperetin.橙皮素离子共晶体中的构象三态性。
Cryst Growth Des. 2022 Nov 2;22(11):6390-6397. doi: 10.1021/acs.cgd.2c00861. Epub 2022 Oct 4.
9
Supramolecular Synthon Promiscuity in Phosphoric Acid-Dihydrogen Phosphate Ionic Cocrystals.磷酸-磷酸二氢根离子共晶体中的超分子合成子混杂现象。
Cryst Growth Des. 2022 May 4;22(5):3333-3342. doi: 10.1021/acs.cgd.2c00150. Epub 2022 Apr 19.
10
Selecting a stable solid form of remdesivir using microcrystal electron diffraction and crystal structure prediction.利用微晶电子衍射和晶体结构预测选择瑞德西韦的稳定固态形式。
RSC Adv. 2021 May 12;11(28):17408-17412. doi: 10.1039/d1ra03100g. eCollection 2021 May 6.
Pharm Res. 1993 Mar;10(3):317-27. doi: 10.1023/a:1018967717781.
4
Solid-state nuclear magnetic resonance (NMR) spectra of pharmaceutical dosage forms.药物剂型的固态核磁共振(NMR)光谱
Pharm Res. 1993 Feb;10(2):197-203. doi: 10.1023/a:1018922407786.
5
Kinetic study of the polymorphic transformations of phenylbutazone.
J Pharm Sci. 1984 Oct;73(10):1453-60. doi: 10.1002/jps.2600731034.
6
Pharmaceutical applications of polymorphism.多晶型现象的药物应用。
J Pharm Sci. 1969 Aug;58(8):911-29. doi: 10.1002/jps.2600580802.
7
Some physicochemical properties of glassy indomethacin.
Chem Pharm Bull (Tokyo). 1986 Oct;34(10):4314-21. doi: 10.1248/cpb.34.4314.
8
Physicochemical properties of crystalline forms of ethynylestradiol solvates: comparison of thermal behavior with X-ray crystal structure.
J Pharm Sci. 1989 Apr;78(4):274-80. doi: 10.1002/jps.2600780403.
9
X-ray crystallographic characterization of two polymorphs of 8-(2-methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-(2- propynyl)-imidazo [1,2-a]pyridine.
J Pharm Sci. 1990 Mar;79(3):189-95. doi: 10.1002/jps.2600790302.
10
Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability.通过溶液量热法测定β-内酰胺抗生素的定量结晶度:与稳定性的相关性。
J Pharm Sci. 1978 Jun;67(6):767-73. doi: 10.1002/jps.2600670609.